Cargando…
Treatment-Resistant Depression. Part A /
Major depressive disorder (MDD) is a common but deteriorating illness worldwide with high comorbidity. The World Health Organization has estimated that MDD would be the leading cause of human disability by 2030. However, many patients with depression fail to respond to antidepressant treatment. Such...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands ; Oxford, United Kingdom ; Cambridge MA :
Elsevier,
2023.
|
| Edición: | First edition. |
| Colección: | Progress in brain research ;
v. 278. |
| Temas: | |
| Acceso en línea: | Texto completo |
| Sumario: | Major depressive disorder (MDD) is a common but deteriorating illness worldwide with high comorbidity. The World Health Organization has estimated that MDD would be the leading cause of human disability by 2030. However, many patients with depression fail to respond to antidepressant treatment. Such treatment-resistant depression (TRD) is associated with worse clinical outcomes, higher suicidality, and a huge socioeconomic burden. However, many unresolved issues have been noted, including different terms used for TRD, definition of an adequate antidepressant trial (standard or maximal dosage, duration of an antidepressant treatment, etc.), a lack of consensus on a consistent TRD definition, and so forth. Furthermore, TRD could occur in different age groups, and patients with TRD may suffer from the cooccurrence of many refractory somatic or physical symptoms, such as insomnia, headache, and tinnitus. Although psychosocial stressors are associated with TRD, biological factors also play an important role in its central mechanisms. For example, functional abnormalities in the mood circuits, neuroinflammation, dysregulation in the brain-gut axis, abnormal brain glutamatergic neurotransmissions, and even genetic predispositions are all involved. For a long time, electroconvulsive therapy has been considered effective in TRD, but its use is declining given its potential side effects during or along with the procedures. Many newer forms of treatment options, such as brain stimulation, next-generation antidepressants (e.g., glutamatergic rapid-acting antidepressants and certain psychedelics) are available for treating TRD. To provide a better treatment for TRD, psychological intervention is also critical, and for some chronic or highly refractory patients, psychiatric rehabilitation could be the key to fewer relapses of depressive episodes and better quality of life. |
|---|---|
| Descripción Física: | 1 online resource (176 pages) : illustrations |
| Bibliografía: | Includes bibliographical references and index. |
| ISBN: | 9780323957793 032395779X |